Arthur F Ryan sold $98k of REGN
director at REGENERON PHARMACEUTICALS, INC.. 100 shares at an average of $982.05, traded Mar 1, 2024, filed Mar 5, 2024.
Score components
- +15RoleDirector
- +10Trade size$98k at market
- 0Share of holdings soldSold 0.5% of holdings
- +15Cluster6 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001968202-24-000084, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 1, 2024 | SOpen-market sale Common Stock10b5-1 | -1 | $967.50 | $968 | 18,381 | Mar 5, 2024 |
| Mar 1, 2024 | SOpen-market sale Common Stock10b5-1 | -1 | $968.66 | $969 | 18,380 | Mar 5, 2024 |
| Mar 1, 2024 | SOpen-market sale Common Stock10b5-1 | -1 | $969.18 | $969 | 18,379 | Mar 5, 2024 |
| Mar 1, 2024 | SOpen-market sale Common Stock10b5-1 | -4 | $970.38 | $3,882 | 18,375 | Mar 5, 2024 |
| Mar 1, 2024 | SOpen-market sale Common Stock10b5-1 | -1 | $971.75 | $972 | 18,374 | Mar 5, 2024 |
| Mar 1, 2024 | SOpen-market sale Common Stock10b5-1 | -2 | $972.29 | $1,945 | 18,372 | Mar 5, 2024 |
| Mar 1, 2024 | SOpen-market sale Common Stock10b5-1 | -1 | $974.78 | $975 | 18,371 | Mar 5, 2024 |
| Mar 1, 2024 | SOpen-market sale Common Stock10b5-1 | -2 | $975.70 | $1,951 | 18,369 | Mar 5, 2024 |
| Mar 1, 2024 | SOpen-market sale Common Stock10b5-1 | -2 | $976.81 | $1,954 | 18,367 | Mar 5, 2024 |
| Mar 1, 2024 | SOpen-market sale Common Stock10b5-1 | -2 | $977.27 | $1,955 | 18,365 | Mar 5, 2024 |
| Mar 1, 2024 | SOpen-market sale Common Stock10b5-1 | -1 | $978.09 | $978 | 18,364 | Mar 5, 2024 |
| Mar 1, 2024 | SOpen-market sale Common Stock10b5-1 | -1 | $979.87 | $980 | 18,363 | Mar 5, 2024 |
| Mar 1, 2024 | SOpen-market sale Common Stock10b5-1 | -1 | $980.21 | $980 | 18,362 | Mar 5, 2024 |
| Mar 1, 2024 | SOpen-market sale Common Stock10b5-1 | -15 | $981.64 | $15k | 18,347 | Mar 5, 2024 |
| Mar 1, 2024 | SOpen-market sale Common Stock10b5-1 | -11 | $982.67 | $11k | 18,336 | Mar 5, 2024 |
| Mar 1, 2024 | SOpen-market sale Common Stock10b5-1 | -12 | $983.61 | $12k | 18,324 | Mar 5, 2024 |
| Mar 1, 2024 | SOpen-market sale Common Stock10b5-1 | -19 | $984.45 | $19k | 18,305 | Mar 5, 2024 |
| Mar 1, 2024 | SOpen-market sale Common Stock10b5-1 | -10 | $985.76 | $9,858 | 18,295 | Mar 5, 2024 |
| Mar 1, 2024 | SOpen-market sale Common Stock10b5-1 | -8 | $986.58 | $7,893 | 18,287 | Mar 5, 2024 |
| Mar 1, 2024 | SOpen-market sale Common Stock10b5-1 | -4 | $987.33 | $3,949 | 18,283 | Mar 5, 2024 |
| Mar 1, 2024 | SOpen-market sale Common Stock10b5-1 | -1 | $988.30 | $988 | 18,282 | Mar 5, 2024 |
Related signals
Other insiders at REGENERON PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 13Weak | REGENERON PHARMACEUTICALS, INC. | Kathryn Guarini director | $340k 400 shares | -40% | |
| 33Weak | REGENERON PHARMACEUTICALS, INC. | Marion McCourt EVP Commercial | $2.0M 2,346 shares | -16% | |
| 12Weak | REGENERON PHARMACEUTICALS, INC. | Kathryn Guarini director | $320k 400 shares | -40% | |
| 18Weak | REGENERON PHARMACEUTICALS, INC. | Huda Y Zoghbi director | $640k 800 shares | -32% | |
| 6Weak | REGENERON PHARMACEUTICALS, INC. | Arthur F Ryan director | $130k 200 shares | -1% | |
| 3Weak | REGENERON PHARMACEUTICALS, INC. | Arthur F Ryan director | $71k 100 shares | -1% | |
| 4Weak | REGENERON PHARMACEUTICALS, INC. | Arthur F Ryan director | $78k 100 shares | -1% | |
| 12Weak | REGENERON PHARMACEUTICALS, INC. | Arthur F Ryan director | $79k 100 shares | -1% | |
| 30Weak | REGENERON PHARMACEUTICALS, INC. | Huda Y Zoghbi director | $1.3M 1,638 shares | -49% | |
| 30Weak | REGENERON PHARMACEUTICALS, INC. | Jason Pitofsky SVP Controller | $1.6M 2,036 shares | -32% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.